Orchid Pharma Limited has informed the Exchange about Transcript
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Orchid Pharma reported Q1 FY26 sales of INR173 crores, a sharp 29% decline from INR244 crores a year ago, citing an unprecedented global slowdown in the antibiotics market with export volumes down ~30% and prices down 15-20%. Operational EBITDA stood at INR14 crores, with gross margins held steady at ~42% as the company chose not to chase volumes in a price war. The major highlight was the acquisition of global rights to Enmetazobactam (trademark Exblifep) from insolvent Allecra, funded entirely through internal accruals with no debt. The deal, expected to close in ~3 months, gives Orchid control over double-digit royalties (~15%) from Advanz Pharma in Europe, with existing licensing in place for Europe, Middle East, UAE and South Africa. Management is targeting a US licensing deal within one year of closing. 7ACA Jammu project is on track for Q1 FY27 commissioning and Cefiderocol for December 2026. The Dhanuka Labs merger is expected in about 6 months.
Near-term outlook remains weak with no revival expected in the current year, but the Enmetazobactam acquisition is a transformative long-term value driver that could significantly boost future earnings once global licensing scales up. The stock may see mixed sentiment — pressure from the steep quarterly revenue drop balanced by the strategic significance of full ownership of a globally approved novel antibiotic.